{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-22-031351","form_type":"8-K","ticker":"LCTX","cik":"0000876343","company_name":"Lineage Cell Therapeutics, Inc.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.816129+00:00","generated_at":"2026-06-22T00:24:36.113641+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Lineage Cell Therapeutics reports Q3 net loss of $6.1M; appoints Jill Howe as CFO","bullets":["Net loss attributable to Lineage of $6.1M ($0.04/share) vs $7.8M ($0.05/share) in Q3 2021.","Total revenue $3.0M, up from $2.3M YoY, driven by Roche collaboration revenue.","Cash, equivalents, and marketable securities $66.4M as of Sep 30, 2022; expected runway into Q3 2024.","Appointed Jill Howe as CFO effective Nov 14, 2022; she has 20+ years biotech finance experience.","Received notice of allowance for two patents covering directed differentiation methods for RPE and OPC cells."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-22-031351","json":"https://secwatch.observer/filing/0001493152-22-031351.json","markdown":"https://secwatch.observer/filing/0001493152-22-031351.md","text":"https://secwatch.observer/filing/0001493152-22-031351.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/876343/000149315222031351/0001493152-22-031351-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/876343/000149315222031351/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T00:24:36.113641+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"e2579403c54f1f9b4c57ebbaa52e3426de15e5f2","claim":"Lineage Cell Therapeutics, Inc. reported the third quarter of 2022 results: revenue approximately $3.0 million.","evidence_excerpt":"generated primarily from licensing fees, royalties, collaboration revenues, and research grants. Total revenues for the three months ended September 30, 2022 were approximately $3.0 million, a net increase of $0.7 million as compared to $2.3 million for the same period in 2021. The increase was driven by collaboration and licensing revenue recognized from deferred","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/876343/000149315222031351/0001493152-22-031351-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter of 2022"},{"label":"Revenue","value":"approximately $3.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}